Tyrosine Pharma Changes Name to Zocere, Inc.

January 16, 2014 08:00 AM Eastern Standard Time
ALBUQUERQUE, N.M.--(BUSINESS WIRE)--Tyrosine Pharma, Inc., a New Mexico-based pharmaceutical company, has changed its name to Zocere, Inc. The shift in nomenclature reflects the company's focus on expanding its portfolio of injectable, neuroprotectant drugs.
Commenting on the name change, Zocere President and CEO Wayne Laslie said there are few treatment options for neurological trauma, particularly stroke, which translates into an opportunity for new and novel therapeutic solutions.
"We all know someone who has been struck down by stroke and how frustrating it is for physicians and family members to have so few treatment options. Zocere is working to change that by developing injectable, brain protecting drugs that have the potential to reduce deaths, long-term disability and the financial impact of stroke," said Laslie.
The development of neuroprotection drugs is badly needed. Stroke is the second leading cause of death worldwide and No. 1 cause of long-term disability. The financial impact of stroke is also significant; in 2010 alone, the cost of health care, medications, and missed work to the U.S. economy was $73.7 billion. Current treatment options for blood clot-induced ischemic stroke—which accounts for 87 percent of strokes—are limited and little used.
Zocere is licensing a STEP peptide from STC.UNM developed at the University of New Mexico and is developing an injectable drug designed to protect patients from brain injury by arresting the progression of brain damage caused by reduced blood flow. While the initial target is stroke, the drug shows promise in treating other brain trauma such as concussion.
About Zocere, Inc.
Headquartered in Albuquerque, New Mexico, Zocere, Inc., is a startup pharmaceutical company developing injectable, neuroprotectant drugs intended to combat stroke and other neurological trauma. Zocere is led by a team of seasoned pharmaceutical industry executives with extensive experience in drug commercialization. Visit www.Zocere.com.
Lux + Associates
Melanie Lux, 803-331-4794

Suggested Articles

Researchers are studying the retrovirus KoRV-A, which is spreading among koalas, to gain new insights into how DNA evolves.

Shionogi and Hsiri Therapeutics first joined forces last year in a licensing and R&D deal focused on tuberculosis and non-tuberculous lung infections.

The efficacy results suggest the experimental oral therapy, abrocitinib, has a shot at challenging the blockbuster biologic incumbent.